OTHERS_CITABLE
Complete Content of this Issue and Cover Content
http://ijbc.ir/article-1-676-en.pdf
2016-07-10
0
0
REVIEW_ARTICLE
Role of Stem Cell Transplantation in the Treatment of Burkitt Lymphoma; A Systematic Review
Background: Burkitt lymphoma is a common subtype of non-Hodgkin lymphoma in children. It has a rapid and aggressive clinical course with frequent involvement of bone marrow and central nervous system. Systemic chemotherapy is the mainstay of the treatment for this malignancy in children. In this systematic review, we discuss autologous and allogeneic hematopoietic stem cell transplantation (HSCT) and its indications in pediatric patients with Burkitt lymphoma.
Methods: The Medline (PubMed) database was searched using all keywords and phrases. The studies were identified by utilizing a combination of MeSH terms, such as Burkitt lymphoma, stem cell transplantation, autologous transplantation and allogeneic transplantation. Articles which were not published as full articles (conference proceedings excluded) were excluded. Relevant articles published during 2000-2015 were included.
Results: 13 articles met the inclusion criteria and were discussed.
Conclusion: Both autologous and allogeneic HSCT may improve survival in patients with BL. Autologous HSCT is mainly considered for patients with high-risk features of BL at presentation; however, allo-HSCT with non-myeloablative conditioning regimens are preferred for advanced stages and relapsed/refractory disease.
http://ijbc.ir/article-1-646-en.pdf
2016-06-25
29
32
Hematopoietic stem cell transplantation
Burkitt lymphoma
Mature B cell leukemia
Autologous transplantation
Allogenic transplantation
Soheila
Zareifar
1
AUTHOR
Babak
Abdolkarimi
b.abdolkarimi@yahoo.com
2
AUTHOR
Mohadreza
Bordbar
3
AUTHOR
Mehran
Karimi
4
AUTHOR
Fazl
Saleh
5
AUTHOR
Omidreza
Zekavat
6
AUTHOR
ORIGINAL_ARTICLE
The Efficacy of Single Dose Rasburicase in Prevention or Treatment of Tumor Lysis Syndrome in Children
Background: Tumor lysis syndrome (TLS) is a major metabolic complication in patients with malignancy after initiation of chemotherapy or spontaneously without treatment. The role of Rasburicase (a recombinant urate-oxidase enzyme) in prevention and treatment of TLS has been demonstrated in recent years. We aimed to investigate the efficacy of a single dose of rasburicase in reducing the risk of TLS in children at high risk.
Methods: we conducted a retrospective analysis of 560 children with various malignancies in a single referral center. On the basis of the reference values previously established in our center hyperuricemia and TLS were defined. Tumor lysis syndrome development was the primary outcome. 48 children with a mean age of 7.1 years (range: 3 months to 15.8 years) developed tumor lysis syndrome. The most common malignancies were B-precursor acute lymphoblastic leukemia (ALL) (45%) followed by non-Hodgkin lymphoma (NHL) and Wilms’ tumor (each 10.4%), respectively. They received normal saline intravenously at a rate of 4-5 L/m2/day in 24-48 hours prior to initiating chemotherapy. Plasma samples were drawn to detect uric acid, calcium, phosphate, potassium, creatinine and blood urea nitrogen (BUN) 4 hours before administering a single dose of IV rasburicase (0.2 mg/kg over 30 minute). Laboratory markers were evaluated again 4 and 24 hours after administering rasburicase.
Results: All patients with diagnosis of TLS had significantly decreased uric acid levels following single dose of rasburicase except 1 patient (2.1%) (P<0.001). Mean plasma uric acid concentration before treatment was 10.0±4.2 mg/dL and 4 hours after treatment declined to 2.2±5.5 (P<0.001). Hyperphosphatemia was also detected in 43.7% of these 48 cases which significantly decreased to 16.7% (P=0.012). Plasma uric acid levels remained low one day after treatment. No side effects were detected.
Conclusion: Rasburicase is a safe and highly effective drug in children with hyperuricemia in the setting of malignancy at risk of developing TLS.
http://ijbc.ir/article-1-672-en.pdf
2016-06-25
33
37
Malignancy
Rasburicase
Hyperurecemia
Tumor lysis syndrome
Samin
Alavi
s.alavi@sbmu.ac.ir
1
AUTHOR
Maryam
Ebadi
2
AUTHOR
Sadaf
Esteghamati
3
AUTHOR
Mohammad
Kaji Yazdi
4
AUTHOR
ORIGINAL_ARTICLE
Fava Bean Ingestion: the Most Important Risk Factor of Hemolysis in G6PD Deficiency in Iran
Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is one of the most known enzyme defects in Iran with various genetic mutations. We aimed to study the predisposing factors of hemolysis in children with G6PD deficiency.
Methods: This study was done during 2007-2012 in two referral centers of Mofid Children’s Hospital and Baqiyatallah Hospital, Tehran, Iran. The hospital records of the patients were fully reviewed and questionnaires for each patient were filled for the date of admission, initial symptoms, initial laboratory results, family history and history of any drug consumption, infection or fava bean ingestion.
Results: Medical records of 192 children with mean age of 4.2 years (1 month to 14 years) were extracted. 68.2% of the cases were male. Hemolytic crises were significantly more common in spring which is the peak time for fava bean consumption and occurred more frequently in those with a family history of G6PD deficiency especially in females. The most common initial symptoms were jaundice (71%), dark color urine (49%), fever (34.4%), and pallor (24.5%), followed by abdominal pain (16.7%). Fava bean intake (93%) was the first etiological agent triggering hemolysis followed by infectious agents and drug consumption. Initial hemoglobin level was significantly lower in male patients.
Conclusion: Regarding the high prevalence of G6PD deficiency in Iran, we should emphasize on education of parents and physicians about the disease and prevention of fava bean ingestion in people with G6PD deficiency.
http://ijbc.ir/article-1-662-en.pdf
2016-06-25
38
42
Fava bean
G6PD deficiency
Hemolysis
Jaundice
Drugs
Zohreh
Kavehmanesh
z_kaveh@hotmail.com
1
AUTHOR
Atie
Arab
sjmohaghegh@gmail.com
2
AUTHOR
Hassan
Abolghasemi
h.abolghasemi@sbmu.ac.irm
3
AUTHOR
Saman
Mohazzab Torabi
smntrb@gmail.com
4
AUTHOR
ORIGINAL_ARTICLE
Epidemiological and Clinicopathological Features of Bladder Cancer: A Report from Kermanshah Province, Iran
Background: Bladder cancer accounts for about 7% of all cancers among adults in Iran. We aimed to evaluate epidemiological and clinicopathological features of bladder cancer in Kermanshah province, west Iran.
Methods: In a descriptive retrospective study, records of patients with bladder cancer referring to Imam Reza Hospital, Kermanshah city, Iran during 2011-2013 were analyzed. Sex, age, smoking habits, patients’ symptoms, histopathology and staging of the tumor were extracted from the records. The grading of the tumor was performed according to the Ash grading system.
Results: 220 patients were registered. 179 (81.4%) were patients men. The mean±SD age for patients at diagnosis was 62.5±15.1 years (range: 14-90 years). 71 (43%) patients were smokers. 165 (75%) patients were from rural areas. Hematuria, dysuria, and frequent or painful urination were reported in 74.5%, 5.5%, and 41.8%, respectively. Transitional cell carcinoma was the most common pathology in 93.2% of the patients. Grade І, ІІ, ІІІ and ІV tumors were observed in 0.5%, 41.5%, 37% and 21% of the patients, respectively.
Conclusion: Bladder cancer occurs most commonly in the elderly. Bladder cancer in Asia is more common in men compared with Europe and Africa. Since hematuria was the main presenting manifestation of the patients with bladder cancer, elderly patients with hematuria should be referred at the earliest convenience for investigation.
http://ijbc.ir/article-1-649-en.pdf
2016-06-25
43
46
Bladder cancer
Clinical manifestation
Age
Sex
Iran
Pathology
Grading
Mazaher
Ramezani
ramezan.r@yahoo.com
1
Department of Pathology, Emam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
AUTHOR
Nima
Naderi
n.naderi@yahoo.com
2
Students Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran
AUTHOR
Afshin
Almasi
afshin.a@yahoo.com
3
Department of Biostatistics and Epidemiology, Kermanshah University of Medical Sciences, Kermanshah, Iran
AUTHOR
Masoud
Sadeghi
sadeghi_mbrc@yahoo.com
4
Cancer Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
AUTHOR
ORIGINAL_ARTICLE
Expression Analysis of Foxo3a Gene in Pediatric Acute Lymphoblastic Leukemia in Southern Iranian Population
Background: Acute lymphoblastic leukemia (ALL), the most common childhood cancer with a peak incidence in children from 2-5 years old, might be associated with poor prognosis and resistance to therapy in specific cytogenetic backgrounds. FoxO3a, a member of the forkhead class ‘O’ (FoxO) transcription factors, is a main downstream target of PI3K/AKT pathway which regulates different variety of biological processes and is overactivated in several human cancers. We aimed to evaluate the aberration of the FoxO3a gene in mRNA level in childhood ALL and compare them with healthy controls.
Methods: Real-time quantitative RT-PCR (qRT-PCR) was used to detect FOXO3a expression in 30 new cases of pediatric ALL and 30 age- and sex-matched healthy children as the control group.
Results: the expression level of the FoxO3a gene was significantly lower in ALL patients compared to healthy controls (P<0.0001), while no difference was observed between the two sub-types B- and T-ALL.
Conclusion: Our study suggested that decreased FoxO3a expression may play an important role in the development of pediatric ALL. FoxO3a could be considered as a molecular target of therapy in ALL malignancy.
http://ijbc.ir/article-1-656-en.pdf
2016-06-25
47
51
FoxO3a
Pediatric ALL
Gene expression
PI3K/AKT pathway
Malihe
Mirzaei
1
Department of Biology, Islamic Azad University, Arsanjan branch, Arsanjan, Iran
AUTHOR
Mahboobeh
Nasiri
2
Department of Biology, Islamic Azad University, Arsanjan branch, Arsanjan, Iran
AUTHOR
Mehran
Karimi
3
Department of Biology, Islamic Azad University, Arsanjan branch, Arsanjan, Iran
AUTHOR
REVIEW_ARTICLE
Preliminary Results of Allogenic Hematopoietic Stem Cell Transplantation of non-M3 Acute Myeloid Leukemia
Background: Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) is used as treatment of choice for patients with acute myeloid leukemia (AML). We aimed to evaluate the prognostic factors in 2-year overall survival of patients with non-M3 AML who underwent allogenic HSCT.
Methods: This is a Cross sectional retrospective study. Demographic data and study of variables such as age, sex, complete remission status, Karnofsky performance status scale at baseline and at time of transplantation, occurrence of GVHD (acute and chronic), relapse and 2-year survival were extracted from records of 49 patients who underwent allogenic HSCT from years 2006-2013 at BMT center in Imam Khomeini Hospital. All Autologous SCTs and M3 cases were not included. All data were analyzed with SPSS software. P<0.05 was considered as statistically significant.
Results: The overall survival rate was 55% in the patients. There was no significant difference in overall survival between complete remission (CR) 1 and CR2. Relapse rate was 6%. Mean 2-year Karnofsky scale was 93.7. Mean admission time following BMT was 22 days which was significantly related to 2-year performance status (P=0.02). Admission complication rate was 22.5% (GVHD 12%). Rate of overall GVHD was 55%, 40% of whom developed chronic GVHD which had a positive effect on 2-year overall survival (OS2).The patient’s first performance state (K1) had a significant correlation with 2-year performance state (P<0.05) and OS2 (P<0.05).
Conclusion: Chronic GVHD and initial Karnofsky performance status scale can be considered as good prognostic factors in patients with AML who undergo allo-HSCT.
http://ijbc.ir/article-1-651-en.pdf
2016-06-25
52
55
Prognostic factors
Karnofsky performance status scale
GVHD
2-year overall survival
Non-M3 AML
Allogenic stem cell transplantation
Autologous stem cell transplantation
Farhad
Shahi
fshahi@yahoo.com
1
Department of Hematology and Medical Oncology, Cancer Research Center, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Marziye
Ghalamkari
dr.ghalam@yahoo.com
2
Internal Medicine Resident, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Seyed Reza
Safayi
fsafano@yahoo.com
3
Department of Hematology and Medical Oncology, Cancer Research Center, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Mehrzad
Mirzania
mmirzania@yahoo.com
4
Department of Hematology and Medical Oncology, Cancer Research Center, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Mahdi
Khatuni
mef_kh@yahoo.com
5
Internal Medicine Resident, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Faeze
Almasi
mania@yahoo.com
6
Internal Medicine Resident, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
CASE_STUDY
Recurrent Venous Thromboembolic Events in a Child with Severe Factor X Deficiency
Congenital factor X deficiency is a rare autosomal recessive bleeding disorder that presents with variable bleeding tendency and prolonged coagulation tests, prothrombin time, and partial thromboplastin time. Thromboembolic events have not been reported in patients with factor X deficiency yet. Herein, we report a patient with factor X deficiency who had recurrent venous thromboembolic events.
http://ijbc.ir/article-1-480-en.pdf
2016-06-25
56
58
Factor X deficiency
Prothrombin time
Partial thromboplastin time
Thromboembolic event
Peyman
Eshghi
1
AUTHOR
Mohammad
Kajiyazdi
2
AUTHOR
Mohammad
Hammoud
drmham82@gmail.com
3
AUTHOR
OTHERS_CITABLE
تست مثبت غیر مستقیم Coomb را به عنوان شاخص از فنوتیپ بمبئی دهنده گروه O .
http://ijbc.ir/article-1-636-fa.pdf
2016-06-25
59
60
Positive Indirect Coomb’s Test as an Indicator of Bombay Phenotype of O-group Donors
http://ijbc.ir/article-1-636-en.pdf
2016-06-25
59
60
Shivali
Sehgal
shivalisehgal@gmail.com
1
Lady Hardinge Medical College
AUTHOR
Priti
Chatterjee
doctorpriti@gmail.com
2
Lady Hardinge Medical College
AUTHOR
Swati
Bharadwaj
doctorswati81@gmail.com
3
Lady Hardinge Medical College
AUTHOR
Chintamani
Pathak
simipathak1@gmail.com
4
Lady Hardinge Medical College
AUTHOR
OTHERS_CITABLE
Leukemia Cutis in a Child with Acute Lymphoblastic Leukemia at Diagnosis and Relapse
http://ijbc.ir/article-1-673-en.pdf
2016-06-25
61
62
Ahmad
Mohammadi Ashiani
1
AUTHOR
Farhad
Madani
2
AUTHOR